🚀 VC round data is live in beta, check it out!
Atossa Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Atossa Therapeutics and similar public comparables like Incannex, Telomir Pharmaceuticals, Cessatech, LTR Pharma and more.
Atossa Therapeutics Overview
About Atossa Therapeutics
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
Founded
2009
HQ
Employees
15
Website
Financials (LTM)
EV
$10M
Atossa Therapeutics Financials
Atossa Therapeutics reported last 12-month revenue of —.
In the same LTM period, Atossa Therapeutics generated — in gross profit and had net loss of ($37M).
Revenue (LTM)
Atossa Therapeutics P&L
In the most recent fiscal year, Atossa Therapeutics reported revenue of — and EBITDA of ($37M).
Atossa Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | — | XXX | ($37M) | XXX | XXX | XXX |
| Net Profit | ($37M) | XXX | ($35M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Atossa Therapeutics Stock Performance
Atossa Therapeutics has current market cap of $51M, and enterprise value of $10M.
Market Cap Evolution
Atossa Therapeutics' stock price is $5.91.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $10M | $51M | 2.4% | XXX | XXX | XXX | $-4.04 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAtossa Therapeutics Valuation Multiples
Atossa Therapeutics trades at (0.3x) EV/EBITDA.
EV / Revenue (LTM)
Atossa Therapeutics Financial Valuation Multiples
As of April 18, 2026, Atossa Therapeutics has market cap of $51M and EV of $10M.
Equity research analysts estimate Atossa Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Atossa Therapeutics has a P/E ratio of (1.4x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $51M | XXX | $51M | XXX | XXX | XXX |
| EV (current) | $10M | XXX | $10M | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (0.3x) | XXX | XXX | XXX |
| EV/EBIT | (0.2x) | XXX | (0.3x) | XXX | XXX | XXX |
| P/E | (1.4x) | XXX | (1.5x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (0.3x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Atossa Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Atossa Therapeutics Margins & Growth Rates
Atossa Therapeutics' revenue in the last fiscal year grew by —.
Atossa Therapeutics' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $2.5M for the same period.
Atossa Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | — | XXX | 34% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $2.5M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Atossa Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Atossa Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Incannex | XXX | XXX | XXX | XXX | XXX | XXX |
| Telomir Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Cessatech | XXX | XXX | XXX | XXX | XXX | XXX |
| LTR Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Nicox | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Atossa Therapeutics M&A Activity
Atossa Therapeutics acquired XXX companies to date.
Last acquisition by Atossa Therapeutics was on XXXXXXXX, XXXXX. Atossa Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Atossa Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialAtossa Therapeutics Investment Activity
Atossa Therapeutics invested in XXX companies to date.
Atossa Therapeutics made its latest investment on XXXXXXXX, XXXXX. Atossa Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Atossa Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Atossa Therapeutics
| When was Atossa Therapeutics founded? | Atossa Therapeutics was founded in 2009. |
| Where is Atossa Therapeutics headquartered? | Atossa Therapeutics is headquartered in United States. |
| How many employees does Atossa Therapeutics have? | As of today, Atossa Therapeutics has over 15 employees. |
| Who is the CEO of Atossa Therapeutics? | Atossa Therapeutics' CEO is Steven C. Quay. |
| Is Atossa Therapeutics publicly listed? | Yes, Atossa Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Atossa Therapeutics? | Atossa Therapeutics trades under ATOS ticker. |
| When did Atossa Therapeutics go public? | Atossa Therapeutics went public in 2012. |
| Who are competitors of Atossa Therapeutics? | Atossa Therapeutics main competitors are Incannex, Telomir Pharmaceuticals, Cessatech, LTR Pharma. |
| What is the current market cap of Atossa Therapeutics? | Atossa Therapeutics' current market cap is $51M. |
| Is Atossa Therapeutics profitable? | No, Atossa Therapeutics is not profitable. |
| What is the current net income of Atossa Therapeutics? | Atossa Therapeutics' last 12 months net income is ($37M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.